Depression

The FDA's recommendations serve to inform potential research sponsors on development protocols for psychedelics and to solicit comment from industry.

Your daily dose of clinical news you may have missed.

Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).

Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, comment on the perception of major depressive disorder (MDD) within the healthcare community and the clinical and practical implications of is this condition.

Primary care clinicians should screen all adults for the 3 mental health conditions to ensure timely referral for appropriate treatment.

A nationally recognized obesity expert discusses mental health in women with obesity.

In a study of over 1000 children and adolescents, authors identified 4 distinct profiles of psychiatric comorbidity with differing risk for a self-harm event.

Researchers found that reliable improvement of depressive symptoms after psychological therapy was associated with a 12% decrease in CVD risk at any given time.

The AHRQ, Mayo Clinic, AMA, and National Academy of Medicine each recommend actions steps for all organizational levels to help build more supportive environments.

Women with prior HC-associated depression had a higher risk of developing a depressive episode during pregnancy and postpartum than women with non-HC-associated depression.

Your daily dose of clinical news you may have missed.

Pregnant women with prenatal depression were found to be more likely to be diagnosed with new CVD within 2 years of delivery than those without depression.

Your daily dose of clinical news you may have missed.

Four months of meditation improved quality of life and psychological symptoms in patients with CAD, according to research presented at ESC Preventive Cardiology 2023.

AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?

About 60% of dual vapers experienced depression and 52% experienced anxiety, according to findings from a survey of over 2500 youth and young adults.

Rebekah Bernard, MD, family physician and national speaker on physician wellness shares 3 pieces of advice on connecting with colleagues again.

Yale Food Addiction Scale author Ashley Gearhardt, PhD, and National Poll on Healthy Aging director Jeffrey Kullgren, MD, MS, MPH, highlight new survey findings.

Primary care is increasingly the setting for mental health discussions, diagnosis, and treatment, underscoring the need for both structural and process change.

Your daily dose of clinical news you may have missed.

Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.

Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.

Reductions in depressive symptoms were greater in adolescents aged ≥13 years and in those with a mental illness and/or depression diagnosis, according to systematic review and meta-analysis.

The novel oral agent is administered once daily for 14 days and has demonstrated rapid and sustained improvement in symptoms across trials.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.

Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.

Mental health issues among health care professionals have always been normal; now that we can acknowledge them, we must, says a family physician and wellness advocate.

Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.